Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 2/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | STAT1 | P42224 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845170 | 0.89 | GALR3 (0.40) | GALR3NR2F2SMN1; SMN2KDM4ERXFP1 | |
| SCHEMBL4835656 | 0.87 | TSHR (0.35) | SMN1; SMN2KDM4ERXFP1HPGDHSD17B10 | |
| SCHEMBL4843173 | 0.87 | GALR3 (0.36) | GALR3NR2F2SMN1; SMN2KDM4EHPGD | |
| SCHEMBL4842544 | 0.85 | GALR3 (0.36) | GALR3NR2F2SMN1; SMN2KDM4ERXFP1 | |
| SCHEMBL4843194 | 0.85 | GALR3 (0.36) | GALR3NR2F2KDM4EHSD17B10NPC1 | |
| SCHEMBL4845126 | 0.83 | KMT2A (0.35) | GALR3NR2F2SMN1; SMN2KDM4EHPGD | |
| SCHEMBL4835901 | 0.82 | RAB9A (0.42) | SMN1; SMN2KDM4ERXFP1HPGDHSD17B10 | |
| SCHEMBL4845137 | 0.81 | KMT2A (0.37) | GALR3NR2F2SMN1; SMN2KDM4EHPGD | |
| SCHEMBL4844711 | 0.76 | RAB9A (0.37) | GALR3NR2F2RAB9AKMT2AMEN1 | |
| SCHEMBL4838306 | 0.76 | PDE4A (0.32) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7371859-B2 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-7145006-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-12-05 | — | — | US | disclosed |
| US-7125994-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-10-24 | — | — | US | disclosed |
| US-20060030709-A1 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2006-02-09 | — | — | US | disclosed |
| US-20060008835-A1 | PNA monomer and precursor | KIM SUNG K | 2006-01-12 | — | — | US | disclosed |
| US-20060003374-A1 | Method of making PNA oligomers | KIM SUNG K | 2006-01-05 | — | — | US | disclosed |
| US-20050283005-A1 | PNA monomer and precursor | KIM SUNG K | 2005-12-22 | — | — | US | disclosed |
| US-6969766-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-29 | — | — | US | disclosed |
| US-20050250785-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20050250786-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20030225252-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030709-A1 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | RNGTT, POLL, RNMT | GALR3 3761/4885NR2F2 3364/4885SMN1; SMN2 1591/4885 |
| US-20050283005-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | GALR3 2428/4885NR2F2 3993/4885SMN1; SMN2 1665/4885 |
| US-20050250785-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | GALR3 2428/4885NR2F2 3993/4885SMN1; SMN2 1665/4885 |
| US-20030225252-A1 | PNA monomer and precursor | PNISR, RNGTT, NCL | GALR3 2238/4885NR2F2 3367/4885SMN1; SMN2 1232/4885 |
| US-20060008835-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | GALR3 2428/4885NR2F2 3993/4885SMN1; SMN2 1665/4885 |
| US-20050250786-A1 | PNA monomer and precursor | PNISR, RNGTT, NPR1 | GALR3 2356/4885NR2F2 3847/4885SMN1; SMN2 1887/4885 |
| US-20060003374-A1 | Method of making PNA oligomers | RNGTT, POLL, PNISR | GALR3 1949/4885NR2F2 3790/4885SMN1; SMN2 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.